Sight Sciences (SGHT) Return on Capital Employed (2021 - 2026)
Sight Sciences' (SGHT) quarterly Return on Capital Employed came in at 37.79% in Q1 2026, up 222.0% year-on-year from 11.74% in Q1 2025, and down 6.71% quarter-over-quarter from 35.42% in Q4 2025.
Sight Sciences (SGHT) Return on Capital Employed (2021 - 2026) Analysis & Trends
Sight Sciences' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 37.79% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 222.0% year-over-year to 37.79% in Q1 2026; TTM through Mar 2026 was 37.79%, a 222.0% increase from a year earlier, with the FY2025 full-year figure at 31.43%, up 485.0% from the prior year.
- Return on Capital Employed declined to 37.79% in Q1 2026 per SGHT's latest filing, from 35.42% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.09% in Q1 2022 and bottomed at 42.75% in Q2 2025.
- The 5-year median for Return on Capital Employed is 37.86% (2022), against an average of 37.65%.
- Across the five-year window, Return on Capital Employed plunged 2278 bps in 2022 and soared 577 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 41.7% in 2022, then increased by 14 bps to 35.93% in 2023, then dropped by 10 bps to 39.56% in 2024, then rose by 10 bps to 35.42% in 2025, then fell by 7 bps to 37.79% in 2026.
- Per Business Quant, the three latest SGHT Return on Capital Employed figures stand at 37.79% (Q1 2026), 35.42% (Q4 2025), and 42.28% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Sight Sciences | 253.53 Mn | 168.57 Mn | 16.98 Mn | -37.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.79% |
| Dec 31, 2025 | -35.42% |
| Sep 30, 2025 | -42.28% |
| Jun 30, 2025 | -42.75% |
| Mar 31, 2025 | -40.01% |
| Dec 31, 2024 | -39.56% |
| Sep 30, 2024 | -37.42% |
| Jun 30, 2024 | -37.24% |
| Mar 31, 2024 | -36.43% |
| Dec 31, 2023 | -35.93% |
| Sep 30, 2023 | -37.94% |
| Jun 30, 2023 | -40.50% |
| Mar 31, 2023 | -41.82% |
| Dec 31, 2022 | -41.70% |
| Sep 30, 2022 | -37.86% |
| Jun 30, 2022 | -31.34% |
| Mar 31, 2022 | -24.09% |
| Dec 31, 2021 | -18.92% |
| Sep 30, 2021 | -27.99% |